Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | CHEMBL374350 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.02 | 0.7 |
mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | Gefitinib | FIMM | pan-cancer | AAC | -0.055 | 0.7 |
mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |